2016 American Transplant Congress
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.
Introduction:HLA specific antibodies detection (HSA) and that of Donor Specific Antibodies (DSA) were revolutionized by the introduction of solid phase assays (Luminex®), therefore making these…2016 American Transplant Congress
Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.
Antithymocyte globulin (ATG) is recommended over IL-2 receptor antagonist (IL2) in high-risk recipients for induction immunosuppression. However, “high-risk” status has not been defined in an…2016 American Transplant Congress
Outcomes in Elderly Renal Transplant Recipients Using Thymoglobulin or Interleukin-2 Receptor Antagonist Induction.
1Pharmacy, University of Illinois, Chicago; 2Transplant Surgery, University of Illinois, Chicago.
Background: Approximately 20% of all renal transplants performed in the US in 2014 occurred in elderly patients. Elderly patients are known to be at higher…2016 American Transplant Congress
Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.
Background: Dosing of rabbit anti-thymocyte globulin (rATG) induction in renal transplant recipients is highly variable by transplant center. Optimizing rATG dose becomes extremely important for…2016 American Transplant Congress
Anti-Thymocyte Globulin Induction Does Not Increase the Risk of Thrombotic Events in Kidney Transplantation: A Matched Case-Control Study.
Background: Anti-thymocyte globulin (ATG) is the most commonly used induction agent in kidney transplantation (KTx). To date, case reports and in vitro analyses have suggested…2016 American Transplant Congress
Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction.Aim of this study was to evaluate the efficacy and safety of preemptive prophylaxis of CMV infection in kidney transplant recipients (KTx) receiving polyclonal antibodies…2016 American Transplant Congress
Evaluating Posttransplant BKV-Specific T Cell Responses in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
Department of Surgery, Duke University, Durham, NC.
Belatacept-based maintenance regimens prevent acute allograft rejection following alemtuzumab induction, and patients so treated maintain intact anti-CMV and -EBV T cell immune responses without viral…2016 American Transplant Congress
Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients.
1Nephrology, Charité, Berin, Germany; 2Rheumatology, Charité, Berlin, Germany.
BACKGROUND:Rituximab off-label use is common in solid organ transplantation. It is used in patients with antibody-mediated rejections, in AB0-incompatible renal transplantation, in pre-sensitized organ recipients…2016 American Transplant Congress
A Retrospective Analysis of Rabbit Antithymocyte Globulin Dosing, MELD, Race, and Weight on Infection and Rejection Rates in Liver Transplantation.
Department of Pharmacy, Stanford Health Care, Stanford, CA.
INTRODUCTION: Rabbit antithymocyte globulin (rATG) use in liver transplantation is uncommon. At our center, induction therapy is comprised of rATG dosed at 1 – 2…2016 American Transplant Congress
Anti-Thymocyte Globulin Induced Thrombocytopenia and Bleeding After Kidney Transplantation.
Background: Bleeding is a significant challenge after renal transplantation. Anti-thymocyte globulin (ATG) induced thrombocytopenia may increase bleeding after kidney transplantation (KTx), but this association has…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- Next Page »